{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:23:53Z","timestamp":1790256233700,"version":"4.1.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.tox.2014.03.009","type":"journal-article","created":{"date-parts":[[2014,4,7]],"date-time":"2014-04-07T21:45:23Z","timestamp":1396907123000},"page":"62-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"special_numbering":"C","title":["Construction and analysis of a human hepatotoxicity database suitable for QSAR modeling using post-market safety data"],"prefix":"10.1016","volume":"321","author":[{"given":"Xiao","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi L.","family":"Kruhlak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.tox.2014.03.009_bib0005","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4236\/pp.2013.41012","article-title":"Hepatoprotective effect of vitamin C (ascorbic acid)","volume":"4","author":"Adikwu","year":"2013","journal-title":"Pharmacol. Pharm."},{"issue":"13","key":"10.1016\/j.tox.2014.03.009_bib0010","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1002\/sim.3586","article-title":"Bayesian pharmacovigilance signal detection methods revisited in a multiple comparison setting","volume":"28","author":"Ahmed","year":"2009","journal-title":"Stat. Med."},{"key":"10.1016\/j.tox.2014.03.009_bib0015","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3923\/jpt.2011.218.233","article-title":"Hepatoprotective influence of vitamin C on thioacetamide-induced liver cirrhosis in Wistar male rats","volume":"6","author":"Al-Attar","year":"2011","journal-title":"J. Pharmacol. Toxicol."},{"issue":"6","key":"10.1016\/j.tox.2014.03.009_bib0020","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/pds.885","article-title":"Disproportionality analysis using empirical Bayes data mining: a tool for the evaluation of drug interactions in the post-marketing setting","volume":"12","author":"Almenoff","year":"2003","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"10","key":"10.1016\/j.tox.2014.03.009_bib0025","doi-asserted-by":"crossref","first-page":"875","DOI":"10.2165\/00002018-200629100-00005","article-title":"Comparative performance of two quantitative safety signalling methods: implications for use in a pharmacovigilance department","volume":"29","author":"Almenoff","year":"2006","journal-title":"Drug Saf."},{"key":"10.1016\/j.tox.2014.03.009_bib0030","series-title":"Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions","author":"Aronson","year":"2006"},{"issue":"5","key":"10.1016\/j.tox.2014.03.009_bib0035","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.etp.2010.10.009","article-title":"Efficacy of vitamin C against liver and kidney damage induced by paraquat toxicity","volume":"64","author":"Awadalla","year":"2012","journal-title":"Exp. Toxicol. Pathol."},{"issue":"11","key":"10.1016\/j.tox.2014.03.009_bib0040","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1093\/ndt\/14.11.2776","article-title":"Dihydropyridine calcium channel blockers: a rare and reversible cause of hepatotoxicity with cholestasis in a CAPD patient","volume":"14","author":"Basile","year":"1999","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.tox.2014.03.009_bib0045","series-title":"Drug-induced Liver Disease","first-page":"345","article-title":"Mechanisms underlying the hepatotoxicity of nonsteroidal anti-inflammatory drugs","author":"Boelsterli","year":"2003"},{"key":"10.1016\/j.tox.2014.03.009_bib0050","series-title":"Drug-induced Liver Disease","first-page":"519","article-title":"Hepatic injury from antiviral agents","author":"Bonacini","year":"2003"},{"issue":"2","key":"10.1016\/j.tox.2014.03.009_bib0055","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf."},{"issue":"15-16","key":"10.1016\/j.tox.2014.03.009_bib0060","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.drudis.2011.05.007","article-title":"FDA-approved drug labeling for the study of drug-induced liver injury","volume":"16","author":"Chen","year":"2011","journal-title":"Drug Discovery Today"},{"issue":"12","key":"10.1016\/j.tox.2014.03.009_bib0065","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1345\/aph.1L315","article-title":"Risk of hepatotoxicity associated with the use of telithromycin: a signal detection using data mining algorithms","volume":"42","author":"Chen","year":"2008","journal-title":"Ann. Pharmacother."},{"issue":"1","key":"10.1016\/j.tox.2014.03.009_bib0070","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/bjc.1979.10","article-title":"Describing the validity of carcinogen screening tests","volume":"39","author":"Cooper","year":"1979","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.tox.2014.03.009_bib0075","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/BF03256796","article-title":"Data mining in drug safety: review of published threshold criteria for defining signals of disproportionate reporting","volume":"24","author":"Deshpande","year":"2010","journal-title":"Pharm. Med."},{"issue":"3.","key":"10.1016\/j.tox.2014.03.009_bib0080","article-title":"Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system","volume":"53","author":"DuMouchel","year":"1999","journal-title":"Am. Statistician"},{"issue":"1","key":"10.1016\/j.tox.2014.03.009_bib0085","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/j.gastro.2011.02.018","article-title":"Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies","volume":"141","author":"Elashoff","year":"2011","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.tox.2014.03.009_bib0090","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"1","key":"10.1016\/j.tox.2014.03.009_bib0095","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2165\/00002018-200932010-00005","article-title":"Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct","volume":"32","author":"Fontana","year":"2009","journal-title":"Drug Saf."},{"issue":"1","key":"10.1016\/j.tox.2014.03.009_bib0100","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1021\/tx900326k","article-title":"Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species","volume":"23","author":"Fourches","year":"2010","journal-title":"Chem. Res. Toxicol."},{"issue":"10","key":"10.1016\/j.tox.2014.03.009_bib0105","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1007\/s00125-009-1491-8","article-title":"Collateral damage: the conundrum of drug safety","volume":"52","author":"Gale","year":"2009","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.tox.2014.03.009_bib0110","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/MOG.0b013e3283383c7c","article-title":"Drug-induced liver injury: a clinical update","volume":"26","author":"Ghabril","year":"2010","journal-title":"Curr. Opin. Gastroenterol."},{"issue":"Suppl. C","key":"10.1016\/j.tox.2014.03.009_bib0115","doi-asserted-by":"crossref","first-page":"C40","DOI":"10.1016\/S0149-2918(98)80007-6","article-title":"Limitations and strengths of spontaneous reports data","volume":"20","author":"Goldman","year":"1998","journal-title":"Clin. Ther."},{"issue":"9","key":"10.1016\/j.tox.2014.03.009_bib0120","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/j.1365-2036.2008.03822.x","article-title":"Review article: The use of potentially hepatotoxic drugs in patients with liver disease","volume":"28","author":"Gupta","year":"2008","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"10","key":"10.1016\/j.tox.2014.03.009_bib0125","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1345\/aph.1E023","article-title":"Early postmarketing drug safety surveillance: data mining points to consider","volume":"38","author":"Hauben","year":"2004","journal-title":"Ann. Pharmacother."},{"issue":"6","key":"10.1016\/j.tox.2014.03.009_bib0130","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2165\/00002018-200730060-00009","article-title":"\u2018Extreme duplication\u2019 in the US FDA Adverse Events Reporting System database","volume":"30","author":"Hauben","year":"2007","journal-title":"Drug Saf."},{"issue":"11","key":"10.1016\/j.tox.2014.03.009_bib0135","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1086\/598929","article-title":"Safety of fluoroquinolone use in patients with hepatotoxicity induced by anti-tuberculosis regimens","volume":"48","author":"Ho","year":"2009","journal-title":"Clin. Infect. Dis."},{"issue":"3","key":"10.1016\/j.tox.2014.03.009_bib0140","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/hep.26175","article-title":"LiverTox: a website on drug-induced liver injury","volume":"57","author":"Hoofnagle","year":"2013","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.tox.2014.03.009_bib0145","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1517\/13543784.16.10.1509","article-title":"The withdrawal of torcetrapib from drug development: implications for the future of drugs that alter HDL metabolism","volume":"16","author":"Howes","year":"2007","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"1","key":"10.1016\/j.tox.2014.03.009_bib0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/toxsci\/kfm021","article-title":"Troglitazone hepatotoxicity: are we getting closer to understanding idiosyncratic liver injury?","volume":"97","author":"Jaeschke","year":"2007","journal-title":"Toxicol. Sci."},{"issue":"2","key":"10.1016\/j.tox.2014.03.009_bib0155","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1055\/s-0032-1316472","article-title":"Liver toxicity of antiretroviral drugs","volume":"32","author":"Jones","year":"2012","journal-title":"Semin. Liver Dis."},{"issue":"6","key":"10.1016\/j.tox.2014.03.009_bib0160","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrd1750","article-title":"Idiosyncratic drug hepatotoxicity","volume":"4","author":"Kaplowitz","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10","key":"10.1016\/j.tox.2014.03.009_bib0165","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/nrd1201","article-title":"Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective","volume":"2","author":"Lewis","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.tox.2014.03.009_bib0170","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/00002018-200932010-00002","article-title":"Determinants of under-reporting of adverse drug reactions: a systematic review","volume":"32","author":"Lopez-Gonzalez","year":"2009","journal-title":"Drug Saf."},{"issue":"4","key":"10.1016\/j.tox.2014.03.009_bib0175","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"Mantel","year":"1959","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.tox.2014.03.009_bib0180","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.yrtph.2009.01.009","article-title":"Identification of structure\u2013activity relationships for adverse effects of pharmaceuticals in humans: Part B. Use of (Q)SAR systems for early detection of drug-induced hepatobiliary and urinary tract toxicities","volume":"54","author":"Matthews","year":"2009","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"1","key":"10.1016\/j.tox.2014.03.009_bib0185","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1586\/17512433.1.1.81","article-title":"Biomarkers of drug-induced adverse events","volume":"1","author":"Mendrick","year":"2007","journal-title":"Expert Rev. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.tox.2014.03.009_bib0190","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1046\/j.1365-2125.1997.05417.x","article-title":"Under-reporting of adverse drug reactions in general practice","volume":"43","author":"Moride","year":"1997","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.tox.2014.03.009_bib0195","series-title":"Mosby's Drug Consult","author":"Mosby","year":"2007"},{"issue":"6","key":"10.1016\/j.tox.2014.03.009_bib0200","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.cgh.2011.02.019","article-title":"Clinical and histopathologic features of fluoroquinolone-induced liver injury","volume":"9","author":"Orman","year":"2011","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.tox.2014.03.009_bib0205","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s10695-011-9544-6","article-title":"The protective role of ascorbic acid (vitamin C) against chlorpyrifos-induced oxidative stress in Oreochromis niloticus","volume":"38","author":"Ozkan","year":"2012","journal-title":"Fish Physiol. Biochem."},{"issue":"14","key":"10.1016\/j.tox.2014.03.009_bib0210","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1503\/cmaj.111823","article-title":"Fluoroquinolone therapy and idiosyncratic acute liver injury: a population-based study","volume":"184","author":"Paterson","year":"2012","journal-title":"CMAJ"},{"issue":"4","key":"10.1016\/j.tox.2014.03.009_bib0215","doi-asserted-by":"crossref","first-page":"e34606","DOI":"10.1371\/journal.pone.0034606","article-title":"Proteomic candidate biomarkers of drug-induced nephrotoxicity in the rat","volume":"7","author":"Rouse","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.tox.2014.03.009_bib0220","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/106002808902300102","article-title":"Phenytoin hepatotoxicity: a review of the literature","volume":"23","author":"Smythe","year":"1989","journal-title":"DICP"},{"issue":"6","key":"10.1016\/j.tox.2014.03.009_bib0225","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2165\/11535340-000000000-00000","article-title":"Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work","volume":"33","author":"Suzuki","year":"2010","journal-title":"Drug Saf."},{"issue":"6","key":"10.1016\/j.tox.2014.03.009_bib0230","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","article-title":"Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database","volume":"25","author":"Szarfman","year":"2002","journal-title":"Drug Saf."},{"issue":"9","key":"10.1016\/j.tox.2014.03.009_bib0235","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1592\/phco.24.13.1099.38090","article-title":"Pharmacovigilance in the 21st century: new systematic tools for an old problem","volume":"24","author":"Szarfman","year":"2004","journal-title":"Pharmacotherapy"},{"issue":"2","key":"10.1016\/j.tox.2014.03.009_bib0240","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/01.ATV.0000256728.60226.77","article-title":"The failure of torcetrapib: was it the molecule or the mechanism?","volume":"27","author":"Tall","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"2","key":"10.1016\/j.tox.2014.03.009_bib0245","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ctrv.2012.09.004","article-title":"Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: a meta-analysis","volume":"39","author":"Teo","year":"2013","journal-title":"Cancer Treat. Rev."},{"issue":"6 (Suppl. 6)","key":"10.1016\/j.tox.2014.03.009_bib0250","first-page":"S2","article-title":"History of levodopa and dopamine agonists in Parkinson's disease treatment","volume":"50","author":"Tolosa","year":"1998","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.tox.2014.03.009_bib0255","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nrgastro.2011.22","article-title":"Mechanisms of drug-induced liver injury: from bedside to bench","volume":"8","author":"Tujios","year":"2011","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.tox.2014.03.009_bib0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yrtph.2008.12.009","article-title":"Identification of structure\u2013activity relationships for adverse effects of pharmaceuticals in humans. Part A: Use of FDA post-market reports to create a database of hepatobiliary and urinary tract toxicities","volume":"54","author":"Ursem","year":"2009","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"2\u20133","key":"10.1016\/j.tox.2014.03.009_bib0265","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0891-6632(91)90059-X","article-title":"Beneficial effect of alacepril, a new angiotensin-converting enzyme inhibitor on albuminuria and glycemic state: an open multicenter trial. Alacepril Study Group","volume":"5","author":"Utsunomiya","year":"1991","journal-title":"J. Diabet. Complications"},{"issue":"10","key":"10.1016\/j.tox.2014.03.009_bib0270","first-page":"885","article-title":"Data mining in pharmacovigilance practice: which algorithm to use?","volume":"31","author":"Yang","year":"2008","journal-title":"Drug Saf."},{"key":"10.1016\/j.tox.2014.03.009_bib0275","series-title":"Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver","article-title":"Drug-induced liver disease","author":"Zimmerman","year":"1999"}],"container-title":["Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300483X14000651?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300483X14000651?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T23:28:13Z","timestamp":1759534093000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300483X14000651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":55,"alternative-id":["S0300483X14000651"],"URL":"https:\/\/doi.org\/10.1016\/j.tox.2014.03.009","relation":{},"ISSN":["0300-483X"],"issn-type":[{"value":"0300-483X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Construction and analysis of a human hepatotoxicity database suitable for QSAR modeling using post-market safety data","name":"articletitle","label":"Article Title"},{"value":"Toxicology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tox.2014.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}